Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

1,000

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

August 31, 2025

Study Completion Date

September 30, 2028

Conditions

Gastric / Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG

SOX plus PD-1 inhibitor

SOX or XELOX plus PD-1 inhibitor

DRUG

SOX Chemotherapy

SOX or XELOX

All Listed Sponsors

lead

Liaoning Cancer Hospital & Institute

OTHER